UCB/€UCB
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About UCB
UCB SA, founded in 1928, is a global biopharmaceutical company headquartered in Brussels, Belgium. The company specializes in the research, development, and commercialization of innovative therapies primarily for the treatment of neurological and immunological disorders. Operating in the healthcare sector, UCB is dedicated to advancing science and addressing unmet medical needs for patients worldwide.
Ticker
€UCB
Sector
Primary listing
BSE
Industry
Pharmaceuticals
Headquarters
Employees
9,215
ISIN
BE0003739530
Website
UCB Metrics
BasicAdvanced
€33B
31.09
€5.61
0.34
€0.97
0.56%
Price and volume
Market cap
€33B
Beta
0.34
52-week high
€198.95
52-week low
€129.35
Average daily volume
167K
Dividend rate
€0.97
Financial strength
Current ratio
1.357
Quick ratio
0.871
Long term debt to equity
29.544
Total debt to equity
30.172
Dividend payout ratio (TTM)
24.32%
Interest coverage (TTM)
5.19%
Profitability
EBITDA (TTM)
1,477
Gross margin (TTM)
71.52%
Net profit margin (TTM)
17.31%
Operating margin (TTM)
13.78%
Effective tax rate (TTM)
8.43%
Revenue per employee (TTM)
€670,000
Management effectiveness
Return on assets (TTM)
3.22%
Return on equity (TTM)
11.21%
Valuation
Price to earnings (TTM)
31.087
Price to revenue (TTM)
5.381
Price to book
3.31
Price to tangible book (TTM)
68.51
Price to free cash flow (TTM)
35.984
Free cash flow yield (TTM)
2.78%
Free cash flow per share (TTM)
484.25%
Dividend yield (TTM)
0.56%
Forward dividend yield
0.56%
Growth
Revenue change (TTM)
18.72%
Earnings per share change (TTM)
218.48%
3-year revenue growth (CAGR)
2.12%
10-year revenue growth (CAGR)
6.29%
3-year earnings per share growth (CAGR)
0.91%
10-year earnings per share growth (CAGR)
17.49%
3-year dividend per share growth (CAGR)
2.26%
10-year dividend per share growth (CAGR)
2.75%
What the Analysts think about UCB
Analyst ratings (Buy, Hold, Sell) for UCB stock.
Bulls say / Bears say
Citi has reiterated a price target of €161 on UCB shares, citing a 'compelling growth outlook' driven by the company's robust product pipeline and consistent dividend history. (Investing.com)
Jefferies has upgraded UCB to 'buy' from 'hold,' increasing peak sales forecasts for the biopharma company's skin disease treatment, Bimzelx, indicating strong market potential. (TradingView News)
UCB's net income is expected to grow this year, suggesting that the market is optimistic about its future earnings potential. (Investing.com)
UCB's return on equity (ROE) is significantly lower than the industry average of 13%, and its net income has shrunk at a rate of 12% over the last five years, indicating potential operational inefficiencies. (Webull)
The company's high three-year median payout ratio of 60% suggests that most profits are being distributed to shareholders, leaving limited funds for reinvestment and potentially hindering future growth. (Webull)
UCB's P/E ratio of 32.1x is substantially higher than the Belgian market average of below 13x, which may indicate overvaluation and could deter potential investors. (Webull)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
UCB Financial Performance
Revenues and expenses
UCB Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for UCB stock?
UCB (UCB) has a market cap of €33B as of July 21, 2025.
What is the P/E ratio for UCB stock?
The price to earnings (P/E) ratio for UCB (UCB) stock is 31.09 as of July 21, 2025.
Does UCB stock pay dividends?
Yes, the UCB (UCB) stock pays dividends to shareholders. As of July 21, 2025, the dividend rate is €0.973 and the yield is 0.56%. UCB has a payout ratio of 24.32% on a trailing twelve-month basis.
When is the next UCB dividend payment date?
The next UCB (UCB) dividend payment date is unconfirmed.
What is the beta indicator for UCB?
UCB (UCB) has a beta rating of 0.34. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.